ARase Therapeutics
2 known investors
Find your way into ARase Therapeutics
938 people in our graph share verified history with the ARase Therapeutics team — schools, employers, funds. One of them is your warm intro.
Noubar Afeyanunlockedknows Paul Chang · together at Massachusetts Institute of Technology (MIT) (overlapped)
knows the team · via Massachusetts Institute of Technology (MIT)
×8knows the team · via Mission Biocapital
×2knows the team · via University at Buffalo
Arase Therapeutics develops first-in-class oncology therapeutics that target ADP-ribose Hydrolases, novel proteins in cancer stress pathways. The company focuses on developing new cancer treatments for patients with various cancer types.
Founders & leadership
PC
Paul ChanginPresident, CEO / CSO and Lead FounderPaul Chang is an MIT-trained researcher who founded ARase Therapeutics and previously co-founded Ribon Therapeutics, where he served as VP of biology overseeing programs that advanced to clinical trials. He currently serves as President, CEO and Chief Scientific Officer of ARase.
WL
W. Lee KrausScientific Founder
MT
Michael TaylorinExecutive ChairmanMichael Taylor is Executive Chairman of ARase Therapeutics, which develops oncology therapeutics targeting ADP-ribose Hydrolases. He has held leadership roles in drug discovery and development, business development, and corporate management.
Investors · 2
Competitors · 6
by search overlap
Atara Biotherapeutics6 shared keywordsAtara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
Aro Biotherapeutics4 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Sarepta Therapeutics4 shared keywordsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Tessera3 shared keywordsTessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases. The company focuses on non-viral delivery methods to enable potentially curative genetic therapies.
Protara Therapeutics3 shared keywordsProtara develops transformative therapies for patients with cancer and rare diseases, applying modern scientific and manufacturing advancements to accelerate drug development.
Samsara Biocapital3 shared keywordsSamsara BioCapital is a venture capital firm that invests in therapeutic and biotech companies, backing scientific teams developing new drugs and medical treatments.
Companies competing with ARase Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does ARase Therapeutics do?
- Arase Therapeutics develops first-in-class oncology therapeutics that target ADP-ribose Hydrolases, novel proteins in cancer stress pathways. The company focuses on developing new cancer treatments for patients with various cancer types.
- Who founded ARase Therapeutics?
- ARase Therapeutics was founded by Paul Chang, W. Lee Kraus.
- Who are ARase Therapeutics's investors?
- ARase Therapeutics's investors include Mission Biocapital, Portal Innovations.